1h Free Analyst Time
Nicotine Addiction - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2019, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.
Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.
Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport Coverage
Nicotine Addiction - Overview
Nicotine Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotine Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotine Addiction - Companies Involved in Therapeutics Development
Antidote Therapeutics Inc
Assuage Pharmaceuticals Inc
Astraea Therapeutics LLC
Avicanna Inc
Camino Pharma LLC
Cessation Therapeutics LLC
Chronos Therapeutics Ltd
CV Sciences Inc
DemeRx Inc
EncepHeal Therapeutics Inc
Eolas Therapeutics Inc
Indivior Plc
MAKScientific LLC
Mind Medicine Inc
Molecular Express Inc
Omeros Corp
Palisades Therapeutics
Sosei Heptares
Sunomix Therapeutics
Tria Bioscience Corp
Nicotine Addiction - Drug Profiles
(cannabidiol + nicotine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-4113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-3009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-4X3256 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Noribogaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
psilocybin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-0069330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CB1 and Agonize CB2 for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URB-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotine Addiction - Dormant Projects
Nicotine Addiction - Discontinued Products
Nicotine Addiction - Product Development Milestones
Featured News & Press Releases
Aug 05, 2019: Antidote Therapeutics progresses optimization of the nicotine-degrading enzyme, NicA2, for potential use in treating nicotine addiction
Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure
Jul 11, 2017: CV Sciences Appoints Dr. Amy M. McCord as Director of Drug Development
Jun 19, 2017: CV Sciences Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA
May 02, 2017: CV Sciences Announces Pre-IND Meeting Date with FDA
May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Nicotine Addiction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Nicotine Addiction - Pipeline by Antidote Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Assuage Pharmaceuticals Inc, H2 2019
Nicotine Addiction - Pipeline by Astraea Therapeutics LLC, H2 2019
Nicotine Addiction - Pipeline by Avicanna Inc, H2 2019
Nicotine Addiction - Pipeline by Camino Pharma LLC, H2 2019
Nicotine Addiction - Pipeline by Cessation Therapeutics LLC, H2 2019
Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2019
Nicotine Addiction - Pipeline by CV Sciences Inc, H2 2019
Nicotine Addiction - Pipeline by DemeRx Inc, H2 2019
Nicotine Addiction - Pipeline by EncepHeal Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Eolas Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Indivior Plc, H2 2019
Nicotine Addiction - Pipeline by MAKScientific LLC, H2 2019
Nicotine Addiction - Pipeline by Mind Medicine Inc, H2 2019
Nicotine Addiction - Pipeline by Molecular Express Inc, H2 2019
Nicotine Addiction - Pipeline by Omeros Corp, H2 2019
Nicotine Addiction - Pipeline by Palisades Therapeutics, H2 2019
Nicotine Addiction - Pipeline by Sosei Heptares, H2 2019
Nicotine Addiction - Pipeline by Sunomix Therapeutics, H2 2019
Nicotine Addiction - Pipeline by Tria Bioscience Corp, H2 2019
Nicotine Addiction - Dormant Projects, H2 2019
Nicotine Addiction - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Nicotine Addiction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Antidote Therapeutics Inc
- Assuage Pharmaceuticals Inc
- Astraea Therapeutics LLC
- Avicanna Inc
- Camino Pharma LLC
- Cessation Therapeutics LLC
- Chronos Therapeutics Ltd
- CV Sciences Inc
- DemeRx Inc
- EncepHeal Therapeutics Inc
- Eolas Therapeutics Inc
- Indivior Plc
- MAKScientific LLC
- Mind Medicine Inc
- Molecular Express Inc
- Omeros Corp
- Palisades Therapeutics
- Sosei Heptares
- Sunomix Therapeutics
- Tria Bioscience Corp
